Compare BUR & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | AVDL |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Guernsey | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2010 | 1996 |
| Metric | BUR | AVDL |
|---|---|---|
| Price | $8.92 | $21.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $18.00 | ★ $18.38 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $466,134,000.00 | $248,517,000.00 |
| Revenue This Year | $13.60 | $65.47 |
| Revenue Next Year | $10.53 | $30.88 |
| P/E Ratio | $22.65 | ★ N/A |
| Revenue Growth | N/A | ★ 79.88 |
| 52 Week Low | $8.19 | $6.38 |
| 52 Week High | $15.73 | $23.57 |
| Indicator | BUR | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 59.01 |
| Support Level | $9.23 | $21.34 |
| Resistance Level | $9.30 | $21.55 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.04 | -0.24 |
| Stochastic Oscillator | 10.87 | 11.81 |
Burford Capital Ltd is a finance firm providing litigation finance, insurance, and risk transfer, law firm lending, corporate intelligence and judgment enforcement, and a wide range of investment activities. It operates in two segments: Principal Finance, which allocates capital to legal finance assets from its balance sheet, primarily as capital provision assets and in limited scope through interests in private funds managed by the company; Asset management and other services, which includes the provision of services to the legal industry, including litigation insurance; and other corporate. The geographical segments include the United States, United Kingdom, Singapore, Hong Kong, China, and, Australia.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.